Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Nimustine in Recurrent High Grade Glioma
NCT02698280Phase 2Completed
- Sponsor
- Huashan Hospital
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, nimustine in glioma, sponsored by Huashan Hospital. Started Jul 2015; status: completed.
02
Drugs
bevacizumabnimustine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02698280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698280.